Jaguar Animal Health (JAGX) Earning Somewhat Positive News Coverage, Study Shows
Media headlines about Jaguar Animal Health (NASDAQ:JAGX) have been trending somewhat positive on Saturday, according to Accern Sentiment. The research group scores the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Jaguar Animal Health earned a news sentiment score of 0.15 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 46.4849940476322 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
A number of research firms have weighed in on JAGX. Rodman & Renshaw began coverage on shares of Jaguar Animal Health in a research report on Tuesday, July 11th. They issued a “buy” rating and a $2.00 price objective for the company. HC Wainwright set a $2.00 price target on shares of Jaguar Animal Health and gave the stock a “buy” rating in a research report on Tuesday, July 11th.
Jaguar Animal Health (JAGX) opened at 0.397 on Friday. Jaguar Animal Health has a 12 month low of $0.34 and a 12 month high of $1.53. The company’s market cap is $42.96 million. The stock’s 50 day moving average is $0.53 and its 200 day moving average is $0.75.
ILLEGAL ACTIVITY NOTICE: This report was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/09/02/jaguar-animal-health-jagx-earning-somewhat-positive-news-coverage-study-shows.html.
About Jaguar Animal Health
Jaguar Health, Inc, formerly Jaguar Animal Health, Inc, is a natural-products pharmaceuticals company. The Company is focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. The Company, through its subsidiary Napo Pharmaceuticals, Inc, is focused on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.
Receive News & Stock Ratings for Jaguar Animal Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Animal Health Inc. and related stocks with our FREE daily email newsletter.